Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02831387 · ClinicalTrials.gov registry record · Phase 2
Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
A Phase 2 study, sponsored by Parion Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT02831387: Clinical Trial Phase 2 study, sponsored by Parion Sciences.
NCT02831387 is a Phase 2 study that was terminated before completion, run by Parion Sciences. The registered enrollment target is 47 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02831387, a Phase 2 study, was terminated before completion, sponsored by Parion Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of treatment with 0.017% P-321 on Dry Eye Symptoms.
Primary Outcome
Dry Eye symptoms were obtained using the Symptom Assessment in Dry Eye (SANDE) questionnaire. The questionnaire utilizes separate Visual Analog Scales (VAS) for the frequency and the Severity of symptoms. The scores range from 0 to 100 where 0 = Rarely or Very Mild, and 100 = All the Time or Very Severe for the Frequency and Severity of the symptoms, respectively. The Global Score as reported in the Primary Outcome is obtained by taking the square root of the product of the frequency score multi
Interventions
- DRUG P-321 Ophthalmic Solution
- DRUG P-321 Ophthalmic Solution placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
Why NCT02831387 stopped before completion
NCT02831387 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which P-321 Ophthalmic Solution is the first listed.
NCT02831387 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02831387 about?
NCT02831387 is a clinical study titled "Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease". The purpose of this study is to evaluate the effect of treatment with 0.017% P-321 on Dry Eye Symptoms.
What is the current status of trial NCT02831387?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2016-07. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02831387?
The interventions under investigation include: P-321 Ophthalmic Solution (DRUG), P-321 Ophthalmic Solution placebo (DRUG).
Who is sponsoring clinical trial NCT02831387?
This trial is sponsored by Parion Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02831387's enrollment target sits among peer trials
47 1283rd of 2000 higher than 715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia